HAART in India: Heartening prospects &amp; disheartening problems by Jacob John, T.
The war against HIV/AIDS is fought on many fronts.
India's reasonably successful tactics of interventions owe
much to the vision and pioneering leadership of the Indian
Council of Medical Research (ICMR). In 1985 American
scientists developed reagents to detect antibodies to HIV
(then called HTLV-III). The same year, the 'ICMR
Centre of Excellence in Virology' at Christian Medical
College, Vellore, established a laboratory for HIV1-3.  We
searched for evidence of entry or spread of HIV in
southern India, using initially reagents gifted by J.L. Sever
and D. Madden1. Surveys among recipients of multiple
blood transfusions1 and tribals with high prevalence of
sexually transmitted diseases (STDs) gave negative
results (unpublished). In the third survey during February
and March 1986, of sex workers in government's
custodial care in Tamil Nadu, conducted with permission
from the Health Minister H.V. Hande, we found that
infection had already reached Chennai, Madurai and
Vellore 2,3.
HIV positive men with STDs detected in Vellore
completed the picture of the chain of heterosexual
transmission2,4, a finding contrary to the then prevalent
view of exclusive rectal transmission between
homosexual men. The need and norms of screening blood
donors and for counseling before and after testing were
established5,6. The ICMR Centre described infection in
monogamous women, themselves without risk-behaviour,
and its inevitable consequence of vertical transmission7.
Retrospective evidence showed transmission even in
19845. All these pioneering studies, supported by the
ICMR, provided the basis for designing interventions.
With vision and wisdom, the ICMR under the
leadership of (Late) V. Ramalingaswami established HIV
testing centres in every State capital by mid-1986. India
is the first country to track the spread of infection and
estimate prevalence rates by sero-epidemiology. Others
had used surveillance data on clinical AIDS to estimate
infection-prevalence by extrapolation. We knew that
multiple infectious diseases plus immune deficiency of
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under-nutrition would confound and mask the clinical
diagnosis of AIDS in India and disease surveillance was
non-existent. Until the National AIDS Control
Organisation (NACO) set up under the Ministry of
Health and Family Welfare took over in 1992, ICMR
functioned as the public health agency to spread
messages of awareness and prevention, train physicians,
ensure safe blood transfusions and prevent nosocomial
transmission. NACO carried the work forward, increased
testing centres, improved sampling procedures and
strengthened blood-safety and hospital infection control.
Among the entire vertical, single-disease public health
initiatives in India, HIV control appears to be the most
efficient.  However, much remains to be done from the
viewpoint of infected persons, to provide care, treat with
drugs and dignity and eliminate discrimination and breach
of human rights.
NACO had promoted the guidelines for treatment of
opportunistic infections and provided support to
States /Union territories to implement it in public sector
hospitals.  That improved the quality of life of many an
HIV positive person, who would eventually succumb to
AIDS. Appropriate anti-retrovirus therapy is life-saving
for the individual. Like in tuberculosis (TB), three drugs
have to be given simultaneously to prevent the pathogen
developing drug resistance. This combination therapy is
called highly active anti-retrovirus treatment (HAART).
But unlike in tuberculosis, HAART is life-long. The world
in general and India in particular were slow to recognize
that HAART is not only the tool for the individual's
restoration to health, but also an ingredient in public health
intervention for retarding the spread of HIV8,9. When
treatment is part of public health intervention for reducing
the incidence of infection, like in our national health
programmes against tuberculosis, leprosy and malaria,
the Government underwrites the cost of diagnosis and
treatment.  Should not the same principle apply for
HIV/AIDS also? NACO has fortunately accepted this
principle. On the last World AIDS day (1 December
2003), then Union Health Minister Sushma Swaraj
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announced that the government has indeed accepted this
policy to provide HAART to those who suffer from
AIDS. This is in accordance with the World Health
Organisation's intention to treat 3 million with HAART
by 2005, according to the '3 by 5' plan.  On April 1, 2004,
NACO launched the supply of the fixed drug
combination or cocktail of zidovudine, lamivudine
(nucleoside reverse-transcriptase inhibitors, NRTI) and
nevirapine (non-nucleoside reverse trabscriptase inhibitor,
NNRTI) to eight government hospitals in Bangalore,
Chennai, Hyderabad, Imphal, Kohima, New Delhi and
Mumbai. NACO has also initiated training of physicians
in the correct use of HAART. Antiviral treatment will
not only improve quality of life of the afflicted, but also
give hope and courage where neither existed, and
encourage their willing disclosure of infection in order to
receive treatment8. The risk-perception of the uninfected
will thus become more immediate, children will be
protected from infection and discrimination, and through
all these, HAART will become part of the prevention of
spread of HIV infection. Indian pharmaceutical
companies have helped this process by manufacturing
generic drugs and reducing the global market prices of
these highly valued medicines. According to Gulick10,
India-made fixed drug combination of zidovudine,
lamivudine and efavirenz (NNRTI)  recommended for
poor countries by the WHO is right for rich
countries as well.
So far, so good. However, this battlefront is not easy
terrain.  In this issue of IJMR there is a review paper on
obstacles to successful antiviral treatment11. SJ Potter
and colleagues in Sydney, Australia alert us on the
problem of the development of drug resistance during
HAART, due to viral and host factors that facilitate the
emergence of HIV variants. All those who are
concerned with introducing HAART in India must read
this article. The authors elaborate on the contributory
factors for drug resistance, namely the existence of virus
reservoirs within the host, high rates of HIV turnover
and of spontaneous mutation, selective pressure from
drugs, pharmacokinetics of drugs and problems of patient
tolerance/adherence to strict regimens. In addition to
these genuine causes, in India we have another problem,
namely erratic and unscientific drug prescription, the
'therapeutic anarchy'. India's experience with treatment
for TB confirms that therapeutic anarchy prevails in the
country. While there are several reasons for this state
of affairs, one glaring problem was that the academic
institutions (medical colleges and postgraduate training
centers, both in government and private sectors) were
not given due partnership role in designing, training or
implementing the diagnosis and treatment guidelines of
the Revised National TB Control Programme (RNTCP).
Thus generations of doctors have been passing out
learning TB diagnosis and treatment from teachers who
follow by and large textbooks written by specialists in
the West or even in India, who themselves were not
part of the RNTCP designers or partners. Re-training
all of them with RNTCP guidelines is nearly impossible.
Doctors prescribe anti-tuberculosis drugs without full
knowledge of the pluses and minuses of drug
combinations and giving wrong doses and durations of
treatment. Only lately has the RNTCP taken corrective
steps of establishing centres for directly observed
treatment (DOT) for which academic and private
institutions are selected for participation. Although this
modification is in the right direction, it remains 'too little
too late'.  Any registered practitioner of modern medicine
can treat TB using any drug, since all of them are available
through pharmacies. Inappropriate drug use has
contributed to the emergence of multidrug resistant
tuberculosis which is emerging at a worrying rate. We
do not want history repeated with HAART with medical
profession causing the emergence of drug resistant HIV.
NACO must establish precise criteria to commence
HAART, the drug and dose combinations, and the exact
principles and modalities of monitoring those on treatment
and validate them through research. The ICMR must
function as the research wing of the government's health
care and public health programmes. For this, the
Departments of Health and Family Welfare must
articulate their questions and address them to the ICMR.
In the case of RNTCP, such partnership works well, but
not in the case of HIV control. In some rich countries
the principle of 'hit early hit hard' was the original
approach to therapy. That is not necessary in India. As
long as a person has good quality of life in spite of HIV
infection, HAART can be withheld; this makes medical
as well as economic sense. Criteria must be set as to
what clinical conditions are diagnostic of AIDS that
signals the need for HAART. When opportunistic
diseases including tuberculosis are diagnosed, the first
step is to apply specific therapy against them, but not to
start HAART. A point of time will arrive when HAART
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vis the smart intervention. Instead of leaving the decision
tree to the individual physician's own criteria, there must
be a mechanism to ensure strict adhesion to strict criteria,
developed and validated through research. Perhaps the
decision to go on HAART must be made by a panel of
three physicians. CD4 cell counts may not be available
everywhere, but other simple tests such as haemoglobin,
haematocrit, total lymphocyte count etc.,  must be
available for monitoring progress. In case a person
relapses in spite of HAART, there must be access to
more sophisticated tests and expertise to alter the
regimen.  In this century it is not too much to ask to put
every person on HAART on a computer register with
programmed alert for timely follow up. In fact,
computerization will lighten the task, which would be
cumbersome if done manually. As HAART is being
introduced, the exact guidelines of criteria to commence
treatment and methods of monitoring progress must be
made available to all physicians irrespective of
institutional affiliation or independent work style. Every
medical college and postgraduate training centre should
be given the detailed protocols and also appropriate
curriculum material so that uniform teaching could take
place. NACO should prepare such curricular material
and work closely with the Medical Council of India to
introduce them without any more loss of time.  This year
all medical interns and final year students must be targeted
for a short course on HAART.  Next year onwards it
should be included in teaching Pharmacology, Medicine
and Paediatrics. Thus at least tomorrow's doctors will
know what HIV treatment is all about.
In the past we have done some bad things with good
intentions. Thus we have chest diseases clinics more
or less exclusively to detect and treat pulmonary TB
and fever clinics to detect and treat malaria.  The
erstwhile leprosy clinics have been disbanded, but
leprosy diagnosis and treatment have not yet been fully
integrated with primary health care system. Primary
care physicians are inadequately trained in leprosy.
Against this backdrop we have little choice but to begin
with HIV treatment centres, parallel to the TB clinics.
Could not every chest clinic for TB be converted to
TB and HIV centre?  Care should be taken not to infect
HIV positive persons with TB and vice versa in such
centres. Could not HIV therapy also be given with direct
observation/supervision, for DOHAART (directly
observed HAART), as has been successfully
experimented in Haiti?  Will NACO and RNTCP agree
to work together? Will HIV counseling, voluntary
testing and treatment in the same premises inhibit TB
patients coming to chest clinics? This question deserves
an answer through a multi-centre study.
Alternatively, NACO may dialogue with each state
health ministry and develop a list of reputed medical care
institutions in every district and town/city. State AIDS
control societies may be the channel of such dialogue.
Among such carefully chosen institutions, suitable ones
may be selected as HAART centres, if they agree to
comply with all requirements.  This process may take
several months. Care must be taken so that people have
easy access to such treatment centres. NACO must
also develop clear guidelines as to who is eligible for
free-of-charge HAART and who is not.
Obviously all HAART centres must be prepared to
function as voluntary counseling and testing centres as
well. All these must be initiated in parallel processes, so
that HAART can be started in many more centres than
those presently established in seven major cities during
2004 itself. Perhaps some 50-100 centres in
well-established institutions will give us the practical
experience and a list of practical problems to be
addressed when expanding the network to all major
hospitals in the country. They can also act as training
centres for physicians in other centres yet to be opened.
Ultimately there should be sufficient centres of HAART
so that people have access within a reasonable distance.
In order to avoid the haphazard use of antiretroviral drugs
by registered medical practitioners, drug marketing may
be restricted to these centres and taken off of the shelves
of pharmacies. But then, how will persons who are willing
to pay for the drugs themselves get them? These and
many similar issues will have to be addressed and
resolved without delay in order to make the policy of
HAART a reality in India.
T. Jacob John
Member, Editorial Board, IJMR
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